Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Authors
Keywords
Canagliflozin, SGLT2i, Atherosclerosis, Inflammation, APOE knockout mice
Journal
Cardiovascular Diabetology
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-07-26
DOI
10.1186/s12933-018-0749-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
- (2018) Chenke Xu et al. BIOCHEMICAL PHARMACOLOGY
- Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
- (2018) Sarah J. Mancini et al. Scientific Reports
- Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice
- (2017) Farhana Naznin et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cardiovascular outcomes with canagliflozin – is it on the CANVAS?
- (2017) Sheila A Doggrell EXPERT OPINION ON PHARMACOTHERAPY
- The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
- (2017) Yusuke Nakatsu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy
- (2017) Eiji Kutoh et al. Drugs in research & development
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
- (2016) Hiroaki Kusaka et al. Cardiovascular Diabetology
- Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells
- (2016) Eva Kassi et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
- (2016) Ji Hye Han et al. DIABETOLOGIA
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability
- (2016) Jean Marie Ruddy et al. JOURNAL OF VASCULAR RESEARCH
- The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice
- (2016) Weiling Leng et al. MEDIATORS OF INFLAMMATION
- KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis
- (2015) Laura S Shankman et al. NATURE MEDICINE
- Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
- (2015) Michishige Terasaki et al. PLoS One
- MCP-1 Stimulates MMP-9 Expression via ERK 1/2 and p38 MAPK Signaling Pathways in Human Aortic Smooth Muscle Cells
- (2014) Ci-Qiu Yang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Contribution of Intimal Smooth Muscle Cells to Cholesterol Accumulation and Macrophage-Like Cells in Human Atherosclerosis
- (2014) Sima Allahverdian et al. CIRCULATION
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway
- (2013) Ming-liang Chen et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion
- (2012) Hailing Li et al. Cardiovascular Diabetology
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
- (2012) Yin Liang et al. PLoS One
- Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility
- (2011) Jing Li et al. Cardiovascular Diabetology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More